Nanotech Investing Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
Nanotech Investing Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
Nanotech Investing Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress
Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee
Finlay Minerals Appoints an Executive Chairman, President & CEO, and Vice President, Corporate Development
